Inclusion Criteria:  >18 years old Postmenopausal women for whom cataract surgery has been scheduled Stage N2-3; C1-2 according (Lens Opacities classification System) LOCS Willing to sign informed consent and fully participate to all length of the study Patients without any previous medical history of ocular and/or systemic inflammatory, autoimmune or auto inflammatory disease Patient with no history of ocular surgery Patients without any previous or concomitant ocular diseases  Exclusion Criteria:  Patients under topical or systemic anti- inflammatory drugs Patients with a concomitant diagnosis of glaucoma, or on therapy with antiglaucoma drugs Patients on systemic or local therapy with drugs that alter the secretion of the tear film (beta blockers, antidepressants and psychotropics) Patients with a history of allergic, congenital, autoimmune systemic diseases Patients who have undergone previous eye surgery Ocular or peri-ocular malignancies or premalignant conditions Active or suspected ocular or peri-ocular infection. Complicated Cataract Surgery Patients with a positive pregnancy testAllergy or reaction history to study drug Patients who participated in a clinical trial in which an investigational drug was administered within 30 days or 5 half-lives of the study drug